Iovance Biotherapeutics, Inc. (IOVA) CEO Fred Vogt on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 08/04/22
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022GlobeNewsWire • 07/27/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced MelanomaGlobeNewsWire • 05/26/22
Iovance Biotherapeutics, Inc. (IOVA) CEO Dr. Fred Vogt on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 05/05/22
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual MeetingGlobeNewsWire • 04/27/22
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022GlobeNewsWire • 04/26/22
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/25/22
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in MelanomaGlobeNewsWire • 04/05/22
Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant UpsideSeeking Alpha • 03/25/22
Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)GlobeNewsWire • 03/15/22